Published in Gut Pathog on July 29, 2014
Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models. Gastroenterol Res Pract (2015) 0.84
Analyses of the probiotic property and stress resistance-related genes of Lactococcus lactis subsp. lactis NCDO 2118 through comparative genomics and in vitro assays. PLoS One (2017) 0.75
Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis. Microb Cell Fact (2017) 0.75
Daikenchuto (TU-100) shapes gut microbiota architecture and increases the production of ginsenoside metabolite compound K. Pharmacol Res Perspect (2016) 0.75
Variation between the oral and faecal microbiota in a free-living passerine bird, the great tit (Parus major). PLoS One (2017) 0.75
Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis. Front Microbiol (2017) 0.75
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol (1983) 16.48
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology (1990) 11.22
Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest (1993) 10.09
The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol (2003) 8.28
Genetics and pathogenesis of inflammatory bowel disease. Nature (2011) 7.79
Two plasmid-determined restriction and modification systems in Streptococcus lactis. Plasmid (1984) 7.06
The fundamental basis of inflammatory bowel disease. J Clin Invest (2007) 6.84
The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 5.72
Multiple control of interleukin-8 gene expression. J Leukoc Biol (2002) 5.35
Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology (2001) 4.44
Dendritic cells in intestinal immune regulation. Nat Rev Immunol (2008) 4.20
Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med (1996) 4.09
Oral tolerance. Immunol Rev (2005) 3.48
Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol (2004) 3.41
Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol (2005) 3.00
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J Gastroenterol Hepatol (2008) 1.79
NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol (2009) 1.79
Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog (2012) 1.68
IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol (2008) 1.66
Live Lactobacillus rhamnosus [corrected] is essential for the inhibitory effect on tumor necrosis factor alpha-induced interleukin-8 expression. Infect Immun (2004) 1.64
Dextran sodium sulfate (DSS) induces colitis in mice by forming nano-lipocomplexes with medium-chain-length fatty acids in the colon. PLoS One (2012) 1.56
Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. Am J Physiol (1999) 1.55
Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab (1996) 1.53
Alive and dead Lactobacillus rhamnosus GG decrease tumor necrosis factor-alpha-induced interleukin-8 production in Caco-2 cells. J Nutr (2005) 1.43
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Interleukin 8: cells of origin in inflammatory bowel disease. Gut (1996) 1.35
Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol (2009) 1.31
Anti-inflammatory effects of bifidobacteria by inhibition of LPS-induced NF-kappaB activation. World J Gastroenterol (2006) 1.21
Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol (2007) 1.21
New Lactococcus strain with immunomodulatory activity: enhancement of Th1-type immune response. Microbiol Immunol (2004) 1.20
MAP kinases contribute to IL-8 secretion by intestinal epithelial cells via a posttranscriptional mechanism. Am J Physiol Cell Physiol (2002) 1.16
Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol (2003) 1.14
Synergy of IL-23 and Th17 cytokines: new light on inflammatory bowel disease. Neurochem Res (2009) 1.10
Spontaneously developing chronic colitis in IL-10/iNOS double-deficient mice. Am J Physiol Gastrointest Liver Physiol (2000) 1.07
Progress in genomics, metabolism and biotechnology of bifidobacteria. Int J Food Microbiol (2011) 1.05
Probiotics inhibit TNF-alpha-induced interleukin-8 secretion of HT29 cells. World J Gastroenterol (2004) 1.03
Inflammatory bowel disease, gut bacteria and probiotic therapy. Int J Med Microbiol (2009) 1.03
Anti-inflammatory properties of dairy lactobacilli. Inflamm Bowel Dis (2011) 1.00
Screening of intestinal microflora for effective probiotic bacteria. J Agric Food Chem (2001) 0.99
Dendritic cells and (CD4+)CD25+ T regulatory cells: crosstalk between two professionals in immunity versus tolerance. Front Biosci (2006) 0.99
Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett (2013) 0.95
Probiotics in the development and treatment of allergic disease. Gastroenterol Clin North Am (2012) 0.93
New insights into the immunological changes in IL-10-deficient mice during the course of spontaneous inflammation in the gut mucosa. Clin Dev Immunol (2012) 0.92
Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice. Int Immunopharmacol (2009) 0.89
A xylose-inducible expression system for Lactococcus lactis. FEMS Microbiol Lett (2004) 0.88
Lactococci as probiotic strains: adhesion to human enterocyte-like Caco-2 cells and tolerance to low pH and bile. Lett Appl Microbiol (1999) 0.85
Antiviral effects of a probiotic Enterococcus faecium strain against transmissible gastroenteritis coronavirus. Arch Virol (2012) 0.83
Importance of IL-10 modulation by probiotic microorganisms in gastrointestinal inflammatory diseases. ISRN Gastroenterol (2011) 0.83
Comparative study of the protective capacity against Salmonella infection between probiotic and nonprobiotic Lactobacilli. J Appl Microbiol (2012) 0.80
High sugar and butter (HSB) diet induces obesity and metabolic syndrome with decrease in regulatory T cells in adipose tissue of mice. Inflamm Res (2015) 0.77
Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact (2017) 0.75